Drug intelligence / Profile preview

BI 14332

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 14332 is an oral small molecule inhibitor of dipeptidyl peptidase 4 (DPP4), also known as CD26 antigen. It was developed by Boehringer Ingelheim for the treatment of type 2 diabetes mellitus. As a DPP4 inhibitor, it works by blocking the enzyme dipeptidyl peptidase 4, which increases levels of incretin hormones and thereby enhances insulin secretion and lowers blood glucose levels. The drug belongs to the classes of antihyperglycaemics, piperidines, pyridines, and xanthines. Development was discontinued after phase I clinical trials[1][2][3][4].

Other names: BI 14332 CLBI14332 CLBI-14332 CL

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on BI 14332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 14332.

Explore the full profile